News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
753,985 Results
Type
Article (57057)
Company Profile (253)
Press Release (696660)
Multimedia
Podcasts (185)
Webinars (26)
Section
Business (201004)
Career Advice (3158)
Deals (36864)
Drug Delivery (162)
Drug Development (84602)
Employer Resources (176)
FDA (17477)
Job Trends (16215)
News (349916)
Policy (35008)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (4)
2027 Genetown Standard (5)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (6)
Academia (2975)
Academic (1)
Accelerated approval (55)
ADA (49)
Adcomms (40)
Allergies (197)
Alliances (50375)
ALS (234)
Alzheimer's disease (1953)
Antibody-drug conjugate (ADC) (544)
Approvals (17846)
Artificial intelligence (799)
ASCO (345)
Autoimmune disease (357)
Automation (62)
Bankruptcy (368)
Best Places to Work (12450)
BIOSECURE Act (22)
Biosimilars (247)
Biotechnology (134)
Bladder cancer (210)
Brain cancer (81)
Breast cancer (828)
Cancer (6496)
Cardiovascular disease (549)
Career advice (2689)
Career pathing (52)
CAR-T (380)
CDC (74)
Celiac Disease (3)
Cell therapy (1030)
Cervical cancer (51)
Clinical research (73621)
Collaboration (2342)
Company closure (8)
Compensation (1495)
Complete response letters (102)
COVID-19 (2978)
CRISPR (123)
C-suite (1280)
Cystic fibrosis (166)
Data (8677)
Decentralized trials (3)
Denatured (53)
Depression (189)
Dermatology (97)
Diabetes (692)
Diagnostics (7500)
Digital health (65)
Diversity (12)
Diversity, equity & inclusion (42)
Drug discovery (370)
Drug pricing (240)
Drug shortages (38)
Duchenne muscular dystrophy (317)
Earnings (83851)
Editorial (78)
Employer branding (22)
Employer resources (158)
Events (123044)
Executive appointments (1190)
FDA (21515)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (19)
Frontotemporal dementia (36)
Funding (1909)
Gene editing (264)
Generative AI (69)
Gene therapy (821)
GLP-1 (1254)
Government (5253)
Grass and pollen (7)
Guidances (419)
Healthcare (20967)
Hematology (197)
HIV (93)
Huntington's disease (64)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (115)
Immunology and inflammation (348)
Immuno-oncology (114)
Indications (206)
Infectious disease (3371)
Inflammatory bowel disease (241)
Inflation Reduction Act (14)
Influenza (144)
Intellectual property (320)
Interviews (625)
IPO (17167)
IRA (58)
Job creations (4075)
Job search strategy (2165)
JPM (72)
Kidney cancer (23)
Labor market (104)
Layoffs (660)
Leadership (53)
Legal (8372)
Liver cancer (108)
Longevity (35)
Lung cancer (865)
Lymphoma (470)
Machine learning (64)
Management (64)
Manufacturing (1184)
MASH (226)
Medical device (14969)
Medtech (15128)
Mergers & acquisitions (21025)
Metabolic disorders (1790)
mRNA (251)
Multiple sclerosis (200)
NASH (24)
Neurodegenerative disease (499)
Neuropsychiatric disorders (125)
Neuroscience (3675)
Neurotech (1)
NextGen: Class of 2026 (7260)
Non-profit (5069)
Now hiring (79)
Obesity (854)
Opinion (367)
Ovarian cancer (241)
Pain (284)
Pancreatic cancer (349)
Parkinson's disease (415)
Partnered (34)
Patents (643)
Patient recruitment (761)
Peanut (69)
People (62830)
Pharmaceutical (86)
Pharmacy benefit managers (37)
Phase 1 (22808)
Phase 2 (32296)
Phase 3 (24344)
Pipeline (9739)
Policy (385)
Postmarket research (2787)
Preclinical (9696)
Press Release (67)
Prostate cancer (343)
Psychedelics (68)
Radiopharmaceuticals (369)
Rare diseases (1251)
Real estate (6144)
Recruiting (75)
Regulatory (27420)
Reports (42)
Research institute (2711)
Resumes & cover letters (498)
Rett syndrome (43)
RNA editing (26)
RSV (95)
Schizophrenia (194)
Series A (321)
Series B (236)
Service/supplier (13)
Sickle cell disease (127)
Special edition (32)
Spinal muscular atrophy (184)
Sponsored (50)
Startups (3742)
State (2)
Stomach cancer (20)
Supply chain (142)
Tariffs (103)
The Weekly (129)
Vaccines (1245)
Venture capital (127)
Weight loss (582)
Women's health (130)
Worklife (24)
Date
Last 7 days (635)
Last 30 days (2804)
Last 365 days (32253)
2026 (15930)
2025 (32168)
2024 (37186)
2023 (42297)
2022 (53642)
2021 (58365)
2020 (57225)
2019 (50698)
2018 (38443)
2017 (34816)
2016 (34197)
2015 (39648)
2014 (31535)
2013 (26493)
2012 (28144)
2011 (28703)
2010 (26132)
Location
Africa (990)
Alabama (101)
Alaska (7)
Arizona (339)
Arkansas (16)
Asia (45834)
Australia (8133)
California (14167)
Canada (3962)
China (1559)
Colorado (610)
Connecticut (631)
Delaware (438)
Europe (103647)
Florida (2125)
Georgia (464)
Hawaii (3)
Idaho (66)
Illinois (1186)
India (99)
Indiana (659)
Iowa (23)
Japan (590)
Kansas (135)
Kentucky (56)
Louisiana (60)
Maine (89)
Maryland (1721)
Massachusetts (10372)
Michigan (407)
Minnesota (790)
Mississippi (7)
Missouri (162)
Montana (36)
Nebraska (29)
Nevada (153)
New Hampshire (91)
New Jersey (3771)
New Mexico (33)
New York (3742)
North Carolina (1865)
North Dakota (11)
Northern California (7139)
Ohio (441)
Oklahoma (26)
Oregon (48)
Pennsylvania (2806)
Puerto Rico (30)
Rhode Island (52)
South America (1346)
South Carolina (87)
South Dakota (2)
Southern California (5615)
Tennessee (224)
Texas (2284)
United States (50604)
Utah (425)
Vermont (1)
Virginia (359)
Washington D.C. (86)
Washington State (1153)
West Virginia (4)
Wisconsin (153)
Wyoming (2)
753,985 Results for "moberg pharma ab formerly known as moberg derma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Moberg Pharma has secured exercise of warrants and entered into a top guarantee free of charge - June 11, 2024
Moberg Pharma AB has received subscription intentions, subscription commitments and top guarantee commitments totaling approximately SEK 113.5 million, related to the warrants of series 2023:1, from a few external professional investors and the Company’s largest shareholder, Östersjöstiftelsen.
June 11, 2024
·
7 min read
Press Releases
Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2026
May 4, 2026
·
6 min read
Press Releases
Notice of Annual General Meeting in Ascelia Pharma AB
March 30, 2026
·
40 min read
Press Releases
Cipher Pharmaceuticals Partner Moberg Pharma AB Reports Topline Data in MOB-015 Phase 3 Study
December 10, 2024
·
7 min read
Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%
Moberg Pharma announces that 17,776,856 warrants of series 2023:1 were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%.
June 24, 2024
·
6 min read
Press Releases
Announcement from the Annual General Meeting of Vicore Pharma Holding AB (publ)
May 6, 2026
·
7 min read
Drug Development
Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America
Moberg Pharma AB has completed the recruitment of 384 patients with onychomycosis for the ongoing MOB-015 phase 3 study in North America.
October 6, 2023
·
3 min read
Drug Development
Cipher Pharmaceuticals Partner Moberg Pharma AB Provides Update on MOB-015 Phase 3 Study
September 13, 2024
·
6 min read
Press Releases
Recludix Pharma Announces Preclinical Data Demonstrating Efficacy Comparable to Monoclonal Antibodies Targeting IL-4/IL-13 Signaling Pathways and Differentiated Safety Profile of Oral STAT6 Inhibitor REX-8756 (also known as SAR448755) in a Model of Atopic Dermatitis
May 17, 2026
·
3 min read
Drug Development
MOB-015 is recommended for approval in EU: Moberg Pharma
Moberg Pharma AB hereby announces that the Decentralized Procedure has ended with a positive outcome and that MOB-015 is recommended for national approval in 13 European countries for the treatment of mild to moderate fungal infections of the nails in adults.
June 28, 2023
·
8 min read
1 of 75,399
Next
